Socioeconomic aspects of ACE inhibition in the secondary prevention in cardiovascular diseases.
Cardiovascular diseases are the leading causes of morbidity and mortality in the industrialized world and have become a major economic burden.
Therefore, not only ethical and medical but also economic reasons suggest more intense efforts in primary and secondary prevention of cardiovascular and, especially, coronary artery disease.
The prevention of the progression of heart failure and of the risks inherent in left ventricular dysfunction, including development of heart failure, reinfarctions, and death, are major cornerstones in the ambitious but economically balanced use of our resources.
Mots-clés Pascal : Cardiopathie coronaire, Inhibiteur enzyme, Peptidyl-dipeptidase A, Peptidyl-dipeptidases, Proteinases, Hydrolases, Enzyme, Rapport coût bénéfice, Economie santé, Insuffisance cardiaque, Hospitalisation, Chimiothérapie, Traitement, Homme, Vasodilatateur, Antihypertenseur, Appareil circulatoire pathologie, Cardiopathie, Angiotensin converting enzyme
Mots-clés Pascal anglais : Coronary heart disease, Enzyme inhibitor, Peptidyl-dipeptidase A, Peptidyl-dipeptidases, Proteinases, Hydrolases, Enzyme, Cost benefit ratio, Health economy, Heart failure, Hospitalization, Chemotherapy, Treatment, Human, Vasodilator agent, Antihypertensive agent, Cardiovascular disease, Heart disease
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 94-0682585
Code Inist : 002B02F04. Création : 09/06/1995.